Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 10217 - 10224 of 11621 results
Our Law360 Article Analyzing CPSC's Proposal to Expand Disclosure of Company & Product Information
February 27, 2014| Blog| Viewpoint
Puerto Rico Senate Not in a New York State of Mind?
February 27, 2014| Blog| Viewpoint
Unprecedented HIPAA Fine May Mean Increased Scrutiny and Penalties
February 26, 2014| Blog| Viewpoint
ML Strategies Posts Weekly Health Care Reform Update on February 24, 2014
February 26, 2014| Blog| Viewpoint
SEC Approves Revised Semi-Annual Data Reporting Requirements for Section 529 Plan Underwriters
February 26, 2014| Blog| Viewpoint
The SEC Speaks About FCPA
February 25, 2014| Blog| Viewpoint
En Español: HHS Agencies Issue Model Notices of Privacy Practices in Spanish
February 24, 2014| Blog| Viewpoint
The Top 10 Changes Made to the 2012 Proposed Rule Under the Affordable Care Act’s Employer Shared Responsibility Rules by Recently Issued Final Regulations
February 24, 2014| Advisory| Viewpoint
News & Press Releases
Mintz Announces New Members
December 20, 2024
Mintz announces the election of eight attorneys to Members, effective January 1, 2025. The newly promoted Members join the ranks of the firm’s growing membership, including six new lateral Members who joined the firm in 2024.
Mintz represented the US Department of Energy (DoE) Loan Programs Office (LPO) in the closing of a $1.45 billion loan guarantee to Hanwha Q Cells Georgia, Inc. (QCells), a leading North American crystalline silicon solar manufacturer.
Dealmaking Dormant No More
December 17, 2024
International Chair of Life Sciences Cheryl Reicin recently participated in a Q&A with Pharmaceutical Executive in which she discusses the ongoing effects of the pandemic on dealmaking trends in the pharmaceutical industry. Cheryl specifically mentions how M&A activity began to rise again in 2024 after slowing in 2023, and that she expects acquisitions to continue picking up in 2025.